secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001730463-26-000032
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus reports FY2025 AUCATZYL net revenue $74.3M; guides FY2026 $120-135M
---------------------------------------------------------------------------

- Q4 2025 AUCATZYL net revenue $23.3M; full-year $74.3M, primarily from U.S. sales.
- FY2025 net loss $287.5M ($1.08/share); cash & equivalents $300.7M at Dec 31.
- FY2026 revenue guidance $120-135M; expects shift to positive gross margin in 2026.
- UK launch commenced January 2026 after NICE evaluation; ROCCA real-world data confirm safety/efficacy.
- Pipeline: initial obe-cel data in progressive MS (BOBCAT) and AL amyloidosis (ALARIC) expected YE 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046326000032/0001730463-26-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046326000032/autl-20260327.htm
  HTML page:      https://secwatch.observer/filing/0001730463-26-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer